Camurus AB (publ) (FRA:7CA)

Market Cap	3.39B -6.6%
Revenue (ttm)	204.71M +0.0%
Net Income	61.25M -5.6%
EPS	1.02 -6.2%
Shares Out	n/a
PE Ratio	55.37
Forward PE	33.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	56.00
Previous Close	56.25
Day's Range	56.00 - 57.55
52-Week Range	40.60 - 67.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 15, 2026

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neu...

• Industry: Pharmaceutical Preparations
• Founded: 1991
• Employees: 316
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7CA

Financial Performance

In 2025, Camurus AB's revenue was 2.27 billion, an increase of 21.30% compared to the previous year's 1.87 billion. Earnings were 735.57 million, an increase of 71.70%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 17, 2026

Data Sources Report a data error